Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

X
Search
Drug Profile

Piclidenoson - Can-Fite Biopharma

Alternative Names: CF 101; IB-MECA; SI 615

Latest Information Update: 31 May 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Can-Fite BioPharma
  • Developer Can-Fite BioPharma; Fondazione Telethon
  • Class Amides; Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Antivirals; Eye disorder therapies; Iodobenzenes; Neuroprotectants; Purine nucleosides; Ribonucleosides; Small molecules
  • Mechanism of Action Adenosine A3 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Plaque psoriasis
  • Phase II COVID 2019 infections
  • Preclinical Oculocerebrorenal syndrome
  • Discontinued Colorectal cancer; Dry eyes; Glaucoma; Ocular hypertension; Osteoarthritis; Rheumatoid arthritis; Solid tumours; Uveitis

Most Recent Events

  • 31 May 2024 Can-Fite Biopharma plans pivotal phase-III trials for Plaque psoriasis in the second half of 2024
  • 30 Jan 2024 Ewopharma exercises its right to expand the distribution agreement with Can-Fite Biopharma to include the indication of pancreatic cancer
  • 29 Jan 2024 Phase-III COMFORT-2 clinical trials in Plaque psoriasis (PO) prior to January 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days

Market Movers of 2025 Webinar

This session is built around insights from our in-depth analysis of drug candidates and market shifts expected to shape the pharmaceutical landscape in 2025. We’ll explore two transformative categories (1) Groundbreaking Drug Launches and (2) Patent Expiration & Market Impact. This webinar will also focus on pivotal clinical trials and regulatory milestones, showcasing how data-driven strategies are shaping the development and approval of these market movers.

Register now